In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in ...

March 26, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to ...

Cingulate (CING) reported that as of December 31, 2024, the company had approximately $12.2M in cash and cash equivalents, a $12.1M increase ...

Cingulate (NASDAQ:CING – Get Free Report) is expected to release its earnings data before the market opens on Monday, March ...

Being raised by two therapists isn't easy by any means, but it did give me a unique perspective on my neuroscience research.

In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on Cingulate Inc (CING – Research Report), with a price ...

New research reveals that Type 2 diabetes may impair the brain’s reward and memory processing in ways that mirror early Alzheimer’s disease.

Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...

A research team says high blood sugar levels appear to weaken function in key part of brain, mimicking Alzheimer's.